InvestorsHub Logo
Followers 154
Posts 2653
Boards Moderated 0
Alias Born 01/29/2004

Re: OFP post# 116184

Saturday, 08/19/2017 1:50:24 PM

Saturday, August 19, 2017 1:50:24 PM

Post# of 464083
Leading the Witness?

...there's something in the secret sauce that just makes 2-73 better..yet to be defined and all based on an uncontrolled, selectively reported trial in 25-32 patients. Does that sum it up correctly?



I believe this sort of question in a court of law might be categorized as “leading the witness,” prompting him to express an utterance not in conformity with the evidence at hand.

I’ll answer it, nonetheless.

Should anyone think that “secret sauces” play any part in the science of safe and efficacious drug candidates, they are welcome to such — although that reveals, does it not, a rather questionable ability to discern real science?

The real science is this. The proprietary and unique sigma-1 receptor agonist molecules of Anavex Life Science Corp., particularly Anavex 2-73, have specific configurations and molecular binding sites that spontaneously reconnect dissembled mitochondria/endoplasmic reticula assemblies in malfunctioning neurons, thereby facilitating the restoration of normalized reaction-controlling enzymes that, among other things, clear symptom-causing waste proteins. This occurs without side effects of concern.

Scientists with far greater expertise than any posters on this board have described this in a number of peer-reviewed papers. No one with professional expertise has questioned the ability of Anavex sigma-1 receptor agonists to reconnect mitochondria and endoplasmic reticula.

Skeptics, whether residing under some bridge or elsewhere, hold to the notion that existing murine and human clinical data are insufficient to support any investment position in AVXL. I have never questioned that notion, per se; merely the nebulous evidence (so little) supporting the notion. All readers are welcome to assume their own perspectives on the accuracy and applicability of existing Anavex data regarding an equity position.

Those with doubts, of any degree or nature, are advised (as they will) to await the confirmatory clinical results emerging late this year or next. No secret sauces needed for that.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News